NCT05048589View on ClinicalTrials.gov

Feasibility of Randomizing Danish Citizens Aged 65-79 Years to High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in a Pragmatic Registry-Based Setting

PHASE2CompletedINTERVENTIONAL

Enrollment

12,551

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

May 31, 2022

Study Completion Date

May 31, 2022

Conditions

Influenza

Interventions

DRUG

Standard-Dose Quadrivalent Influenza Vaccine

For the control arm, the standard-dose quadrivalent influenza vaccines Influvactetra® and Vaxigriptetra will be used.

DRUG

High-Dose Quadrivalent Influenza Vaccine

For the control arm, the high-dose quadrivalent influenza vaccine Efluelda®/Fluzone® High-Dose Quadrivalent will be used.

Trial Locations (2)

2860

Danske Lægers Vaccinations Service, Søborg

2900

Cardiovascular Non-Invasive Imaging Research Laboratory, Department of Cardiology, Herlev and Gentofte Hospital, Hellerup

All Listed Sponsors

collaborator

Sanofi Pasteur, a Sanofi Company

INDUSTRY

lead

Tor Biering-Sørensen

OTHER

NCT05048589 - Feasibility of Randomizing Danish Citizens Aged 65-79 Years to High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in a Pragmatic Registry-Based Setting | Biotech Hunter | Biotech Hunter